Artiva Biotherapeutics (ARTV) Competitors $2.05 +0.09 (+4.59%) As of 06/12/2025 04:00 PM Eastern Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsTrendsBuy This Stock ARTV vs. NVCT, INBX, PRQR, MNPR, ELDN, ESPR, VYGR, DERM, DMAC, and OGIShould you be buying Artiva Biotherapeutics stock or one of its competitors? The main competitors of Artiva Biotherapeutics include Nuvectis Pharma (NVCT), Inhibrx (INBX), ProQR Therapeutics (PRQR), Monopar Therapeutics (MNPR), Eledon Pharmaceuticals (ELDN), Esperion Therapeutics (ESPR), Voyager Therapeutics (VYGR), Journey Medical (DERM), DiaMedica Therapeutics (DMAC), and Organigram (OGI). These companies are all part of the "pharmaceutical products" industry. Artiva Biotherapeutics vs. Its Competitors Nuvectis Pharma Inhibrx ProQR Therapeutics Monopar Therapeutics Eledon Pharmaceuticals Esperion Therapeutics Voyager Therapeutics Journey Medical DiaMedica Therapeutics Organigram Artiva Biotherapeutics (NASDAQ:ARTV) and Nuvectis Pharma (NASDAQ:NVCT) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their media sentiment, valuation, profitability, dividends, analyst recommendations, risk, earnings, community ranking and institutional ownership. Which has stronger valuation and earnings, ARTV or NVCT? Artiva Biotherapeutics has higher revenue and earnings than Nuvectis Pharma. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioArtiva Biotherapeutics$251K198.98N/AN/AN/ANuvectis PharmaN/AN/A-$22.26M-$1.13-7.81 Do institutionals and insiders believe in ARTV or NVCT? 96.8% of Nuvectis Pharma shares are owned by institutional investors. 21.4% of Artiva Biotherapeutics shares are owned by insiders. Comparatively, 30.5% of Nuvectis Pharma shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth. Does the MarketBeat Community believe in ARTV or NVCT? Artiva Biotherapeutics received 3 more outperform votes than Nuvectis Pharma when rated by MarketBeat users. Likewise, 100.00% of users gave Artiva Biotherapeutics an outperform vote while only 92.86% of users gave Nuvectis Pharma an outperform vote. CompanyUnderperformOutperformArtiva BiotherapeuticsOutperform Votes16100.00% Underperform VotesNo VotesNuvectis PharmaOutperform Votes1392.86% Underperform Votes17.14% Does the media favor ARTV or NVCT? In the previous week, Artiva Biotherapeutics had 6 more articles in the media than Nuvectis Pharma. MarketBeat recorded 8 mentions for Artiva Biotherapeutics and 2 mentions for Nuvectis Pharma. Nuvectis Pharma's average media sentiment score of 1.87 beat Artiva Biotherapeutics' score of 1.50 indicating that Nuvectis Pharma is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Artiva Biotherapeutics 1 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Nuvectis Pharma 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Do analysts prefer ARTV or NVCT? Artiva Biotherapeutics currently has a consensus target price of $17.80, suggesting a potential upside of 768.29%. Nuvectis Pharma has a consensus target price of $17.00, suggesting a potential upside of 92.53%. Given Artiva Biotherapeutics' higher possible upside, analysts plainly believe Artiva Biotherapeutics is more favorable than Nuvectis Pharma.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Artiva Biotherapeutics 0 Sell rating(s) 0 Hold rating(s) 6 Buy rating(s) 0 Strong Buy rating(s) 3.00Nuvectis Pharma 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 3.00 Is ARTV or NVCT more profitable? Artiva Biotherapeutics' return on equity of 0.00% beat Nuvectis Pharma's return on equity.Company Net Margins Return on Equity Return on Assets Artiva BiotherapeuticsN/A N/A N/A Nuvectis Pharma N/A -155.80%-104.02% SummaryArtiva Biotherapeutics beats Nuvectis Pharma on 8 of the 11 factors compared between the two stocks. Get Artiva Biotherapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for ARTV and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding ARTV and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ARTV vs. The Competition Export to ExcelMetricArtiva BiotherapeuticsBiological Products IndustryMedical SectorNASDAQ ExchangeMarket Cap$47.75M$3.12B$5.61B$8.62BDividend YieldN/A1.56%5.28%4.17%P/E RatioN/A32.9027.1719.96Price / Sales198.98466.20410.96157.63Price / CashN/A168.6838.2534.64Price / BookN/A3.427.064.69Net IncomeN/A-$72.35M$3.23B$248.14M7 Day Performance-2.38%3.01%0.77%0.95%1 Month PerformanceN/A20.80%9.67%5.74%1 Year PerformanceN/A-17.10%32.02%14.73% Artiva Biotherapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ARTVArtiva Biotherapeutics2.6697 of 5 stars$2.05+4.6%$17.80+768.3%N/A$47.75M$251K0.0081Positive NewsAnalyst UpgradeAnalyst RevisionNVCTNuvectis Pharma2.985 of 5 stars$8.98-4.6%$17.00+89.3%+32.8%$187.63MN/A-7.748News CoveragePositive NewsINBXInhibrx2.9309 of 5 stars$12.96-3.8%N/A-13.3%$187.61M$200K0.11166Positive NewsUpcoming EarningsPRQRProQR Therapeutics2.1822 of 5 stars$1.78+7.2%$8.00+349.4%+7.8%$187.28M$18.97M-5.56180Positive NewsAnalyst RevisionMNPRMonopar Therapeutics2.9001 of 5 stars$30.01-5.4%$55.33+84.4%+655.8%$183.51MN/A-15.2310ELDNEledon Pharmaceuticals2.6389 of 5 stars$3.06+2.0%$12.50+308.5%+1.4%$183.24MN/A-1.5210ESPREsperion Therapeutics4.1032 of 5 stars$0.92+8.1%$6.25+580.4%-58.5%$182.07M$259.57M-1.44200Positive NewsAnalyst RevisionVYGRVoyager Therapeutics4.4301 of 5 stars$3.29+20.1%$13.39+307.0%-58.5%$182.06M$66.96M4.63100Trending NewsAnalyst RevisionHigh Trading VolumeDERMJourney Medical2.3354 of 5 stars$7.81-3.1%$9.88+26.4%+17.3%$181.94M$56.24M-8.3190Positive NewsShort Interest ↑High Trading VolumeDMACDiaMedica Therapeutics1.3513 of 5 stars$4.17+1.5%$8.00+91.8%+55.4%$178.82MN/A-7.4520Short Interest ↑OGIOrganigram0.6322 of 5 stars$1.31-3.0%N/A-8.7%$175.39M$194.09M-3.45860News CoveragePositive News Related Companies and Tools Related Companies NVCT Alternatives INBX Alternatives PRQR Alternatives MNPR Alternatives ELDN Alternatives ESPR Alternatives VYGR Alternatives DERM Alternatives DMAC Alternatives OGI Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ARTV) was last updated on 6/13/2025 by MarketBeat.com Staff From Our PartnersElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | SponsoredAn AI run of epic proportions is only getting startedI just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredWhy Elon put $51 million into thisWhy Elon Musk Just Invested $51 Million Into Brand New “Miracle Metal” Developed by MIT ScientistsTrue Market Insiders | SponsoredThe Robotics Revolution has arrived … and one $7 stock could take off as a result.Something big is brewing in Washington. According to my research, an executive order from President Trump c...Weiss Ratings | SponsoredCollect $7k per month from Tesla’s SECRET dividendI just uncovered a strategy that could pay out up to $7,013 every month—without needing a traditional dividend...Investors Alley | SponsoredSilicon Valley Gold RushA new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredTrump’s true trade war strategyThe media and financial pundits are all misreading Trump’s actions. They think Trump wants to make Canada t...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Artiva Biotherapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Artiva Biotherapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
